A new form of drug drastically improves survival rates of younger women with the most common type of breast cancer, researchers said on Saturday, citing the results of an international clinical trial.
The findings, presented at the annual meeting of the American Society of Clinical Oncology in Chicago, showed that the addition of cell-cycle inhibitor ribociclib increased survival rates to 70 percent after three-and-a-half years.
The mortality rate was 29 percent less than when patients, all under 59 and pre-menopausal, were randomly assigned a placebo.
Lead author Sara Hurvitz said the study focused on a form of breast cancer that is fueled by the hormone estrogen and which accounts for two-thirds of all cases among younger women.
It is generally treated by therapies that block the hormone’s production.
“You actually can get synergy, or a better response, better cancer kill, by adding one of these cell-cycle inhibitors” on top of the hormone blocking therapy, Hurvitz said.
The drug works by inhibiting the activity of cancer-cell promoting enzymes. The treatment is less toxic than traditional chemotherapy, because it more selectively targets cancerous cells, blocking their ability to multiply.
Though advanced breast cancer is less common among younger women, its incidence grew 2 percent per year in the US between 1978 and 2008 for women aged 20 to 39, a previous study showed.
The new trial, which looked at more than 670 cases, included only women who had advanced cancer — stage four — for which they had not received prior hormone-blocking therapy.
“These are patients who tend to be diagnosed later, at a later stage in their disease, because we don’t have great screening modalities for young women,” Hurvitz said.
In addition, patients who develop breast cancer early tend to have more complex cases.
A pill is administered daily for 21 days followed by seven days off to allow the body time to recover, since two-thirds of patients have a moderate to severe drop in white cell count.
Jamie Bennett, a spokeswoman for Novartis, which markets the drug under the brand name Kisqali and funded the research, said it cost US$12,553 for a 28-day dose.
There is no cure for metastatic breast cancer and the majority of the women on the drug will require some form of therapy for the rest of their lives.
Oncologist Harold Burstein of the Dana-Farber Cancer Institute in Boston, who was not involved in the research, said it was “an important study,” having established that the use of the drug “translates into a significant survival benefit for women.”
“Hopefully, these data will enable access for this product for more women around the world, particularly in healthcare systems which assess value rigorously as part of their decisions for national access to drugs,” Burstein added.
‘HYANGDO’: A South Korean lawmaker said there was no credible evidence to support rumors that Kim Jong-un has a son with a disability or who is studying abroad South Korea’s spy agency yesterday said that North Korean leader Kim Jong-un’s daughter, Kim Ju-ae, who last week accompanied him on a high-profile visit to Beijing, is understood to be his recognized successor. The teenager drew global attention when she made her first official overseas trip with her father, as he met with Chinese President Xi Jinping (習近平) and Russian President Vladimir Putin. Analysts have long seen her as Kim’s likely successor, although some have suggested she has an older brother who is being secretly groomed as the next leader. The South Korean National Intelligence Service (NIS) “assesses that she [Kim Ju-ae]
In the week before his fatal shooting, right-wing US political activist Charlie Kirk cheered the boom of conservative young men in South Korea and warned about a “globalist menace” in Tokyo on his first speaking tour of Asia. Kirk, 31, who helped amplify US President Donald Trump’s agenda to young voters with often inflammatory rhetoric focused on issues such as gender and immigration, was shot in the neck on Wednesday at a speaking event at a Utah university. In Seoul on Friday last week, he spoke about how he “brought Trump to victory,” while addressing Build Up Korea 2025, a conservative conference
DEADLOCK: Putin has vowed to continue fighting unless Ukraine cedes more land, while talks have been paused with no immediate results expected, the Kremlin said Russia on Friday said that peace talks with Kyiv were on “pause” as Ukrainian President Volodymyr Zelenskiy warned that Russian President Vladimir Putin still wanted to capture the whole of Ukraine. Meanwhile, US President Donald Trump said that he was running out of patience with Putin, and the NATO alliance said it would bolster its eastern front after Russian drones were shot down in Polish airspace this week. The latest blow to faltering diplomacy came as Russia’s army staged major military drills with its key ally Belarus. Despite Trump forcing the warring sides to hold direct talks and hosting Putin in Alaska, there
North Korea has executed people for watching or distributing foreign television shows, including popular South Korean dramas, as part of an intensifying crackdown on personal freedoms, a UN human rights report said on Friday. Surveillance has grown more pervasive since 2014 with the help of new technologies, while punishments have become harsher — including the introduction of the death penalty for offences such as sharing foreign TV dramas, the report said. The curbs make North Korea the most restrictive country in the world, said the 14-page UN report, which was based on interviews with more than 300 witnesses and victims who had
RSS